Jump to content



Recommended Posts

Visit  https://merckoncologyclinicaltrials.com/en-us/patient/trial/NCT04938817 or call 888-577-8839 for more information

KEYNOTE-B98 - Safety and efficacy study of Pembrolizumab in combination with investigational agents for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in need of second-line therapy. (NCT04938817)

You may be able to join this study if your ES-SCLC has gotten worse.

ES-SCLC is a type of advanced SCLC that has spread to other parts of the body.

The trial drug you get will depend on which group you are placed in. This trial has 4 groups:

Group 1 will get MK-1308A.

Group 2 will get MK-1308A and lenvatinib.

Group 3 will get MK-1308A and MK-4830.

Group 4 will get coformulation favezelimab/pembrolizumab.

You, your trial doctor, and the trial staff will know what you are getting.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.